What is Regentis Biomaterials Ltd. (RGNT) stock price today?

Regentis Biomaterials Ltd. (RGNT) is currently trading at $2.07, up 0.49% today.

What is RGNT P/E ratio?

Regentis Biomaterials Ltd.'s P/E ratio is -0.08. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is Regentis Biomaterials Ltd.'s market cap?

Regentis Biomaterials Ltd. has a market capitalization of $8.15M.

AMEX · Medical - Instruments & Supplies

Regentis Biomaterials Ltd. (RGNT) Stock

$2.07 +0.49% AMEX: RGNT Healthcare

Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life.

Valuation

Metric	Value
Price	$2.07
Market Cap	$8.15M
P/E Ratio	-0.08
P/B Ratio	2.22
P/S Ratio	—
EPS (TTM)	$-24.16
52-Week High	$15.50
52-Week Low	$1.23
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	—
ROA	-107.53%
ROCE	—
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.25
Current Ratio	2.65

Latest News

Regentis Biomaterials Obtains Japanese Patent Allowance for Cartilage Repair Treatment MT Newswires · Jul 20, 2026 Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology ACCESS Newswire · Jul 20, 2026 Regentis Biomaterials (RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process NewMediaWire · Jul 16, 2026 Regentis Biomaterials Gets Approval for Cartilage Product Manufacturing Process From European Regulator MT Newswires · Jul 15, 2026 Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch ACCESS Newswire · Jul 15, 2026

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	—
Quick Ratio	2.65
Interest Coverage	—
Return 1Y	—
Return 3Y	—
Return 5Y	—

Ownership

Insiders Held14.05%

Institutions Held21.01%

Institutions Float Held24.44%

Institutional Holder	Shares	Report Date
AIGH Capital Management LLC	300,000	2026-03-31
Rosalind Advisors, Inc.	251,510	2026-03-31
UBS Group AG	334	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACR	$18.30	+1.05%	701.33	$133.33M	0.00%
ALFCenturion Acquisition Corp.	$10.89	-0.55%	34.45	$391.36M	0.00%
IGNEIgene Biotechnology, Inc.	$0.00	—	-0.10	$15654	0.00%
ISRGIntuitive Surgical, Inc.	$353.10	-2.40%	54.82	$124.74B	0.00%
MAHNMid-Atlantic Home Health Network, Inc.	$0.11	+0.00%	56.25	$1.36M	0.00%

About Regentis Biomaterials Ltd.

Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.

Regentis Biomaterials Ltd. is led by CEO Ehud Geller, employs 10 people, headquartered in IL, publicly traded since 2025.

Regentis Biomaterials Ltd. (RGNT) stock trades at $2.07 with a market capitalization of $8.15M. The stock is valued at a price-to-earnings (P/E) ratio of -0.08, price-to-book of 2.22. Over the past 52 weeks the stock has ranged between $1.23 and $15.50, and currently trades 86.6% below its 52-week high.

On profitability, Regentis Biomaterials Ltd. generates an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.regentis.co.il